Shirouchi, Yuko
Nishimura, Noriko
Mishima, Yuko
Ishihara, Yuko
Asai, Hiroaki
Tamba, Mikako
Hirano, Mitsuhito
Hirano, Kei
Teramoto, Yukako
Yoshida, Kikuaki
Takeuchi, Kengo
Terauchi, Takashi
Maruyama, Dai
Article History
Received: 29 May 2023
Accepted: 3 August 2023
First Online: 22 August 2023
Competing interests
: Y.S. reports honoraria from Chugai, Ezai, and SymBio. N.N. reports consulting fees from Chugai Pharmaceutical Co. Y.M. reports grants from Takeda Pharma, Bristol Myers Squibb, Kyowa Kirin, Taiho, and Eisai, consulting fees from Chugai Pharmaceutical, Roche, and honoraria from Janssen, AstraZeneca, and Takeda. K.T. reports grants from Fujirebio and Daiichi Sankyo, royalties from Sysmex and Nichirei, consulting fees from Nichirei, Nippon Shinyaku, and Meiji, and honoraria from Chugai, Kyowa Kirin, Takeda, Janssen, MSD, Eizai, Celgene, Yakult, and Taiho. D.M. reports grants from Amgen Astellas Biopharma, Kyowa Kirin, Chugai, Takeda, Sanofi, Bristol Myers Squibb, Eisai, Taiho, Celgene, Novartis, Ono, Janssen, Otsuka, Astellas, AbbVie, MSD, and honoraria from Ono, Nippon Shinyaku, Mundipharma, Chugai, MSD, Sanofi, Takeda, Bristol Myers Squibb, Celgene, Janssen, Eisai, Kyowa Kirin, Zenyaku, SymBio, AbbVie, AstraZeneca. The other authors have no competing interests to disclose.